FN just had quite a run - up 25% in a month and people are wondering if there's more juice left in this stock. So what does FN actually do? Fabrinet is basically the manufacturing backbone for high-speed optical components and telecom gear. They're not the brand you see, but they're the ones making the stuff inside data centers and telecom networks that actually moves the data around.

What's catching people's attention right now is their HPC business scaling hard. In Q2 fiscal 2026, HPC hit $85.6 million in revenue, and management is guiding for that to exceed $150 million per quarter in the next couple quarters. That's serious growth trajectory. Add to that the acceleration in Telecom and DCI revenues - basically the infrastructure that connects data centers - and you've got a pretty compelling story for why the stock has been moving.

The guidance for Q3 is also solid. They're looking at 35% year-over-year top-line growth and 40% earnings growth at the midpoint despite some forex headwinds. That kind of consistency tends to attract money.

Now, the competitive landscape is intense. You've got Lumentum, Coherent, and Jabil all playing in similar spaces. Over the past 12 months, FN is up 179.5%, which sounds great until you realize Coherent jumped 288.5% and Lumentum exploded 919.4%. So there's definitely a performance gap there. Though FN did outpace Jabil's 77.7% return.

The valuation is where it gets interesting. FN is trading at 36X forward earnings compared to the sector average of 24.5X and Jabil at 20.3X. That's a premium, though still cheaper than Coherent's 42.5X. The question is whether the growth justifies that multiple.

What I find noteworthy is the pipeline visibility. They've got programs in datacom that are described as quarters away from meaningful revenue, not years. Next-gen 800ZR in telecom hasn't ramped yet, so that's another catalyst sitting there. Plus they're working on co-packaged optics with multiple customers. The balance sheet is also clean - $961.5 million in cash with zero debt.

Earnings estimates have been creeping higher too. Consensus for Q3 is up 3.5% over the past month. So there's positive momentum in revisions, which usually matters more than the stock's current price action.

The real question is whether the 25% move has priced in most of the near-term upside or if there's still room to run as these programs scale. The guidance and pipeline suggest there's more to come, but at these valuations, execution becomes everything.